Company Directory / Biotechnology
PrivateFor profitBiotechnologyNiel, Belgium
eTheRNA immunotherapies
eTheRNA develops immunotherapies that target the fundamental role of dendritic cells in the human immune system.
- Founded
- 2013 13 years ago
- Staff
- 51-100 band, as listed
- Followers
- - on LinkedIn
- Funding
- $112M as listed, currency not stated
Set against six million companies
Size
51-100 people: larger than 75% of companies with a size listed
Age
13 years old.
Reach
Website ranked #7,175,814 in the world for traffic, about 869 visits a month.
What it does
BiotechnologyHealth CareMedical DeviceTherapeutics
Funding, as listed
$112M currency not stated
- Rounds5
- LatestSeries b, Aug 2022
- Investors14, 5 leading
What the source datasets report. We have not watched these rounds ourselves.
Every detail we hold
Everything the source datasets list about eTheRNA immunotherapies, field by field. Contact details are held but never shown.
The company
- Name
- eTheRNA immunotherapies
- Type
- For profit
- Status
- Private
- Founded
- 2013
- Founders
- Kris Thielemans
- Industry
- Biotechnology
- Categories
- Biotechnology, Health Care, Medical Device, Therapeutics
Where
- City
- Niel
- Country
- Belgium
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 51-100
- Web traffic rank
- #7,175,814
- Monthly web visits
- 869
Funding, as listed
- Total
- 111,909,485 (currency not stated)
- Rounds
- 5
- Latest round
- Series b
- Latest round date
- Aug 2022
- Investors
- 14
- Lead investors
- 5
- Listing status
- private
About this record
- Sources
- crunchbase,country:domain-tld
- Last imported
- Sept 2026
Growth, as the source summarises it
eTheRNA immunotherapies may be growing as indicated by several developments in its operations and partnerships. The company has been enabling a growing number of life science and pharma companies, which suggests an expansion of its customer base and possibly its business operations. Additionally, eTheRNA immunotherapies has introduced a novel LNP technology, which could represent an advancement in its product offerings and a potential increase in its market competitiveness. Furthermore, the company's involvement in the manufacturing of mRNA drug substances, as mentioned in a collaboration where it provided the mRNA drug substance, indicates active participation in significant projects within the biotechnology and therapeutics industry.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology in Belgium.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 36,920 companies in Belgium and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.